Genome interpretation using in silico predictors of variant impact
Estimating the effects of variants found in disease driver genes opens the door to
personalized therapeutic opportunities. Clinical associations and laboratory experiments …
personalized therapeutic opportunities. Clinical associations and laboratory experiments …
Small-molecule drug discovery in triple negative breast cancer: current situation and future directions
M Liao, J Zhang, G Wang, L Wang, J Liu… - Journal of medicinal …, 2021 - ACS Publications
Triple negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, but
an effective targeted therapy has not been well-established so far. Considering the lack of …
an effective targeted therapy has not been well-established so far. Considering the lack of …
Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab
J Li, M Ma, X Yang, M Zhang, J Luo, H Zhou, N Huang… - Molecular cancer, 2020 - Springer
Background Triple negative breast cancer (TNBC) remains the most challenging breast
cancer subtype so far. Specific therapeutic approaches have rarely achieved clinical …
cancer subtype so far. Specific therapeutic approaches have rarely achieved clinical …
Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities
R Rosell, AF Cardona, O Arrieta, A Aguilar… - British Journal of …, 2021 - nature.com
Epidermal growth factor receptor (EGFR) mutations in lung adenocarcinoma are a frequent
class of driver mutations. Single EGFR tyrosine kinase inhibitor (TKI) provides substantial …
class of driver mutations. Single EGFR tyrosine kinase inhibitor (TKI) provides substantial …
Targeting the EGFR signaling pathway in cancer therapy: What's new in 2023?
Introduction Epidermal growth factor receptor (EGFR) is frequently amplified, overexpressed,
and mutated in multiple cancers. In normal cell physiology, EGFR signaling controls cellular …
and mutated in multiple cancers. In normal cell physiology, EGFR signaling controls cellular …
ESRP1-mediated biogenesis of circPTPN12 inhibits hepatocellular carcinoma progression by PDLIM2/NF-κB pathway
Y Ji, C Ni, Y Shen, Z Xu, L Tang, F Yu, L Zhu, H Lu… - Molecular Cancer, 2024 - Springer
Background Emerging evidence indicates the pivotal involvement of circular RNAs
(circRNAs) in cancer initiation and progression. Understanding the functions and underlying …
(circRNAs) in cancer initiation and progression. Understanding the functions and underlying …
A phase Ib study of the combination of personalized autologous dendritic cell vaccine, aspirin, and standard of care adjuvant chemotherapy followed by nivolumab for …
Despite the promising therapeutic effects of immune checkpoint blockade (ICB), most
patients with solid tumors treated with anti-PD-1/PD-L1 monotherapy do not achieve …
patients with solid tumors treated with anti-PD-1/PD-L1 monotherapy do not achieve …
Syntenin-1-mediated small extracellular vesicles promotes cell growth, migration, and angiogenesis by increasing onco-miRNAs secretion in lung cancer cells
Small extracellular vesicles (sEVs) play a pivotal role in tumor progression by mediating
intercellular communication in the tumor microenvironment (TME). Syntenin-1 induces …
intercellular communication in the tumor microenvironment (TME). Syntenin-1 induces …
[HTML][HTML] Targeting undruggable phosphatase overcomes trastuzumab resistance by inhibiting multi-oncogenic kinases
L Wang, Y Lin, Z Yao, N Babu, W Lin, C Chen… - Drug Resistance …, 2024 - Elsevier
Aims Resistance to targeted therapy is one of the critical obstacles in cancer management.
Resistance to trastuzumab frequently develops in the treatment for HER2+ cancers. The role …
Resistance to trastuzumab frequently develops in the treatment for HER2+ cancers. The role …
[HTML][HTML] SHP2 promotes proliferation of breast cancer cells through regulating Cyclin D1 stability via the PI3K/AKT/GSK3β signaling pathway
Y Yuan, Y Fan, Z Gao, X Sun, H Zhang… - Cancer biology & …, 2020 - ncbi.nlm.nih.gov
Objective: The tyrosine phosphatase SHP2 has a dual role in cancer initiation and
progression in a tissue type-dependent manner. Several studies have linked SHP2 to the …
progression in a tissue type-dependent manner. Several studies have linked SHP2 to the …